Niraxostat_product_DataBase

Bioactivity	Niraxostat (Y-700; Piraxostat) is an orally active xanthine oxidoreductase (XOR) inhibitor used in the study of hyperuricemia and other diseases in which XOR may be involved[1].
In Vivo	Niraxostat (Y-700; 1 mg/kg）的口服生物利用度高（84.1%），且几乎不通过肾脏排泄，主要通过肝脏清除[1]。Niraxostat (Y-700; 1-10 mg/kg; 口服; 单剂量）在 oxonate 处理大鼠中，可剂量依赖性地降低血浆尿酸盐水平[1]。Niraxostat (Y-700; 0.3-3 mg/kg; 口服; 单剂量) 在正常大鼠中，剂量依赖性地减少尿排泄中的尿酸盐和尿囊素，同时增加排泄中的次黄嘌呤和黄嘌呤[1]。Niraxostat (Y-700) 在正常大鼠中的药代动力学分析[1]Route
CAS	206884-98-2
Formula	C16H17N3O3
Molar Mass	299.32
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Fukunari A, et al. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion. J Pharmacol Exp Ther. 2004 Nov;311(2):519-28.

PeptideDB